// App-Quantinova.ai

1252 : The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to < 100 × 109/L) at Baseline

Researchers

Presenter

  • Paola Guglielmelli

Principal Investigators

  • Alessandro Vannucchi

  • Ming-hui Duan

  • Haitao Meng

  • Ling Pan

  • Guangsheng He

  • Srdan Verstovsek

  • Franoise Boyer-Perrard

  • Fiorenza Barraco

  • Dietger Niederwieser

  • Ester Pungolino

  • Anna Marina Liberati

  • Claire Harrison

  • Pantelia Roussou

  • Monika Wroclawska

  • Kevin Majidi

  • Peter AW te Boekhorst

  • Heinz Gisslinger

Medical Centers

  • CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy

  • Hopital Saint-Louis and Universite Paris Diderot, Paris, France

  • Peking Union Medical College Hospital, Beijing, China

  • Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University; Institute of Hematology, Zhejiang University, Zhejiang, China

  • West China Hospital of Sichua University, Chengdu, China

  • First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital, Nanjing, China

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Centre Hospitalier Universitaire, Angers, France, Angers, France

  • Centre Hospitalo-Universitaire Lyon Sud, Lyon, France

  • Department of Hematology, University of Leipzig, Leipzig, Germany

  • Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • Università degli Studi di Perugia,Azienda Ospedaliera Santa Maria di Terni,Terni,Italy

  • Department of Haematology, Guys and St Thomas Hospitals NHS Trust, London, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Department of Immunology, Erasmus Medical Center, Rotterdam, Netherlands

  • Haematologie Haemostaseologie Innere Medizin I, AKH Allgemeines Krankenhaus Wien, Vienna, Austria

Locations

  • Italy

  • France

  • China

  • United States

  • Germany

  • United Kingdom

  • Switzerland

  • Netherlands

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • N-Acylethanolamine acid amidase

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT01317875

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved